

Title (en)
IDENTIFICATION OF DEC, (DENTRITIC AND EPITHELIAL CELLS, 205 kDa), A RECEPTOR WITH C-TYPE LECTIN DOMAINS, NUCLEIC ACIDS ENCODING DEC, AND USES THEREOF

Title (de)
IDENTIFIZIERUNG VON DEC-205, (DENTRITISCHEN UND EPITHELZELLEN, 205 KDA), REZEPTOR MIT C-TYP LEKTIN REGIONEN, DAFÜR KODIERENDE NUKLEINSÄURE UND VERWENDUNGEN DAVON

Title (fr)
IDENTIFICATION DE LA PROTEINE MEMBRANAIRE, INTEGRALE DEC (CELLULES DENDRITQUES ET EPITHELIALES, 205 kDa), UN RECEPTEUR A DOMAINES LECTINIQUES DE TYPE C, DES ACIDES NUCLEIQUES CODANT DEC, AINSI QUE SES APPLICATIONS

Publication
EP 0808366 A1 19971126 (EN)

Application
EP 96906258 A 19960131

Priority
• US 9601383 W 19960131
• US 38152895 A 19950131

Abstract (en)
[origin: WO9623882A1] The present invention relates to the identification and characterization of a receptor associated with antigen presentation in immune responses, endocytosis, and transepithelial transport. Identification of the receptor, its characterization as having ten lectin-binding domains, and evidence of its role in the uptake and processing of oligosaccharides and oligosaccharide-decorated molecules, e.g. glycoproteins, has important ramifications for modifying immune response, and for trans-epithelial transport of molecules. The receptor, or integral membrane protein, termed herein "DEC", is found primarily on dendritic cells, but also found on B cells, brain capillaries, bone marrow stroma, epithelia of intestinal villi and pulmonary airways, as well as cortical epithelium of the thymus and the dendritic cells in the T cell areas of peripheral lymphoid organs. The murine and human counterparts of DEC have an apparent molecular mass of 205 kDa, the murine counterpart has an isoelectric point at pH 7.5, and carbohydrates comprise about 7 kDa of the total mass of murine DEC. The present invention is directed to identification of additional ligands of DEC, which can be advantageously targeted to dendritic cells and other cells that bear DEC. Targeting antigens for presentation by dendritic cells can provide for tolerance when the dendritic cells are quiescent, or for immune stimulation (i.e., vaccination) when the dendritic cells are activated, e.g., by stimulation with a cytokine or lymphokine, such as colony stimulating factor (CSF).

IPC 1-7
C12N 15/12; C07K 14/705; C07K 16/28; A61K 38/17; A61K 39/00; G01N 33/68; A61K 47/48; A61K 45/00

IPC 8 full level
G01N 33/53 (2006.01); **A61K 38/00** (2006.01); **A61K 39/00** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **C07K 14/47** (2006.01); **C07K 14/705** (2006.01); **C07K 16/28** (2006.01); **C12N 5/10** (2006.01); **C12N 15/09** (2006.01); **C12N 15/12** (2006.01); **C12N 15/87** (2006.01); **G01N 33/566** (2006.01); **G01N 33/577** (2006.01)

CPC (source: EP)
A61K 47/6425 (2017.08); **C07K 14/4726** (2013.01); **C07K 14/705** (2013.01); **C12N 15/87** (2013.01); **A61K 38/00** (2013.01); **A61K 39/00** (2013.01); **A61K 2039/5154** (2013.01)

Cited by
US11253579B2; US10953101B2; US11801305B2; US10946079B2; US11654188B2; US10046056B2; US10940209B2; US11793882B2; US10821157B2; US11666638B2; US9850296B2; US10392437B2; US10800838B2; US10919963B2; US11884721B2; US9814780B2; US9878048B2; US9901645B2; US9901646B2; US10265416B2; US10265415B2; US10471155B2; US11246943B2

Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)
WO 9623882 A1 19960808; AU 4970296 A 19960821; AU 716056 B2 20000217; CA 2211993 A1 19960808; EP 0808366 A1 19971126; JP H10513350 A 19981222; MX 9705923 A 19980731

DOCDB simple family (application)
US 9601383 W 19960131; AU 4970296 A 19960131; CA 2211993 A 19960131; EP 96906258 A 19960131; JP 52372696 A 19960131; MX 9705923 A 19970731